Eli Lilly (LLY) came out with quarterly earnings of $3.34 per share, missing the Zacks Consensus Estimate of $3.52 per share. This compares to earnings of $2.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.11%. A quarter ago, it was expected that this drugmaker would post earnings of $5.03 per share when it actually produced earnings of $5.32, delivering a surprise of 5.77%.Over the last four quarters, the company has su ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Roche Holding AG (RHHBY) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Roche Holding AG is one of 1000 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different g ...

Pfizer (PFE) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 43.75%. A quarter ago, it was expected that this drugmaker would post earnings of $0.48 per share when it actually produced earnings of $0.63, delivering a surprise of 31.25%.Over the last four quarters, the company has surp ...

Core Insights - AbbVie reported quarterly earnings of $2.46 per share, exceeding the Zacks Consensus Estimate of $2.39 per share, and showing an increase from $2.31 per share a year ago, representing an earnings surprise of 2.93% [1] - The company achieved revenues of $13.34 billion for the quarter, surpassing the Zacks Consensus Estimate by 3.39% and increasing from $12.31 billion year-over-year [2] - AbbVie has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The future performance of AbbVie’s stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $3.09 on revenues of $14.8 billion, and for the current fiscal year, it is $12.20 on revenues of $59.58 billion [7] Industry Context - The Large Cap Pharmaceuticals industry, to which AbbVie belongs, is currently ranked in the top 21% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of AbbVie’s stock may also be influenced by the overall industry outlook and trends [8] Competitor Insights - Eli Lilly, a competitor in the same industry, is expected to report quarterly earnings of $3.52 per share, reflecting a year-over-year increase of 36.4%, with revenues anticipated to be $12.62 billion, up 43.9% from the previous year [9][10]

Merck (MRK) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.07 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 3.26%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $1.69 per share when it actually produced earnings of $1.72, delivering a surprise of 1.78%. Over the last four quarters, the com ...

The most recent trading session ended with Eli Lilly (LLY) standing at $827.54, reflecting a +1.16% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 2.51%. Elsewhere, the Dow gained 2.66%, while the tech-heavy Nasdaq added 2.71%. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a cl ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Pfizer (PFE) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 29. On the othe ...

Company Overview - Eli Lilly (LLY) shares increased by 14.3% to close at $839.96, following a notable trading volume that exceeded typical levels. This rise contrasts with a 12.2% loss over the previous four weeks [1][2]. Drug Development - The stock's surge was driven by positive topline results from the phase III ACHIEVE-1 study of orforglipron for type 2 diabetes (T2D), which showed a significant reduction in A1C levels by 1.3% to 1.6% over 40 weeks. Over 65% of patients on the highest dose achieved A1C levels of 6.5% or lower, and patients lost an average of 16 pounds (7.9%) [2]. Financial Performance - Eli Lilly is projected to report quarterly earnings of $4.44 per share, reflecting a year-over-year increase of 72.1%. Expected revenues are $12.64 billion, up 44.2% from the same quarter last year [3]. Earnings Estimates - The consensus EPS estimate for Eli Lilly has been revised 1.1% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4]. Industry Context - Eli Lilly is part of the Zacks Large Cap Pharmaceuticals industry, where Merck (MRK) also operates. Merck's stock closed 2% higher at $78, but has seen a return of -18.7% over the past month [4].

Group 1: AbbVie Earnings Expectations - AbbVie is expected to report a year-over-year increase in earnings, with an EPS of $2.47, reflecting a change of +6.9%, and revenues of $12.88 billion, up 4.7% from the previous year [3][12] - The earnings report is scheduled for April 25, 2025, and could influence the stock price depending on whether the results meet or exceed expectations [2][4] - The consensus EPS estimate has been revised 0.05% lower in the last 30 days, indicating a slight bearish sentiment among analysts [4][10] Group 2: Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that AbbVie has a negative Earnings ESP of -3.61%, suggesting analysts have become more pessimistic about the company's earnings prospects [10][11] - Despite the negative Earnings ESP, AbbVie holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [11][16] - Historically, AbbVie has beaten consensus EPS estimates in the last four quarters, with a surprise of +1.41% in the most recent quarter [12][13] Group 3: Industry Comparison - Merck, another player in the pharmaceuticals industry, is expected to report an EPS of $2.16, representing a year-over-year change of +4.4%, with revenues projected at $15.48 billion, down 1.9% from the previous year [17] - Merck's consensus EPS estimate has been revised down by 4% over the last 30 days, resulting in an Earnings ESP of -2.04% [18] - Similar to AbbVie, Merck has a Zacks Rank of 3, complicating predictions for an earnings beat [18]

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.78%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2 per share when it actually produced earnings of $2.04, delivering a surprise of 2%.Over the l ...